Konstantinos Stavropoulos

List of Publications by Year
in descending order

92	1,011	516215 16	500791 28
papers	citations	h-index	g-index

92	92	92	1692
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
2	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Current Vascular Pharmacology, 2018, 16, 246-253.	0.8	69
3	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology, 2018, 16, 130-142.	0.8	54
4	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	0.9	45
5	Hypertension in Metabolic Syndrome: Novel Insights. Current Hypertension Reviews, 2020, 16, 12-18.	0.5	42
6	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2019, 24, 4587-4592.	0.9	42
7	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Current Hypertension Reports, 2020, 22, 90.	1.5	35
8	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and metaâ€analysis of randomized, shamâ€controlled, catheterâ€based trials. Journal of Clinical Hypertension, 2020, 22, 572-584.	1.0	29
9	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
10	Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 2020, 38, 1220-1234.	0.3	25
11	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24
12	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
13	Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 375, 88-90.	13.9	17
14	The potential role of statins in treating liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 331-339.	1.4	17
15	Now That Renal Denervation Works, How Do We Proceed?. Circulation Research, 2019, 124, 693-695.	2.0	17
16	Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. New England Journal of Medicine, 2018, 378, 966-968.	13.9	16
17	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16
18	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Current Pharmaceutical Design, 2018, 24, 1879-1886.	0.9	16

#	Article	IF	Citations
19	Hematocrit and Stroke: A Forgotten and Neglected Link?. Seminars in Thrombosis and Hemostasis, 2017, 43, 591-598.	1.5	15
20	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Current Pharmaceutical Design, 2017, 23, 1510-1521.	0.9	15
21	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. Current Vascular Pharmacology, 2020, 19, 323-342.	0.8	15
22	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. Current Pharmaceutical Design, 2017, 23, 1540-1550.	0.9	14
23	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. Gynecological Endocrinology, 2024, 34, 1019-1021.	0.7	13
24	Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. Current Vascular Pharmacology, 2018, 16, 239-245.	0.8	13
25	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Current Clinical Pharmacology, 2019, 13, 261-272.	0.2	13
26	Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 2502-2502.	13.9	10
27	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. Journal of Clinical Hypertension, 2018, 20, 942-948.	1.0	10
28	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus . Vascular Health and Risk Management, 2019, Volume 15, 365-373.	1.0	10
29	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9
30	Sacubitril/valsartan instead of reninâ€angiotensin system inhibition alone: A step forward in resistant hypertension. Journal of Clinical Hypertension, 2018, 20, 65-68.	1.0	9
31	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
32	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
33	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety, 2019, 18, 241-251.	1.0	8
34	Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. Current Pharmaceutical Design, 2019, 24, 3647-3653.	0.9	8
35	Primary Aldosteronism: Novel Insights. Current Hypertension Reviews, 2020, 16, 19-23.	0.5	8
36	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. Current Pharmaceutical Design, 2019, 24, 5508-5516.	0.9	8

#	Article	IF	Citations
37	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. Current Vascular Pharmacology, 2019, 17, 425-428.	0.8	7
38	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Current Pharmaceutical Design, 2019, 24, 5517-5524.	0.9	7
39	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. American Journal of Hypertension, 2016, 29, 662-662.	1.0	6
40	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. Journal of Clinical Hypertension, 2017, 19, 798-800.	1.0	6
41	Pharmacological Management of Type 2 Diabetes Complications. Current Vascular Pharmacology, 2020, 18, 101-103.	0.8	6
42	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 120-126.	0.2	5
43	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. Journal of Sexual Medicine, 2019, 16, 1199-1211.	0.3	5
44	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. European Journal of Internal Medicine, 2020, 77, 153-155.	1.0	5
45	Pharmacological Management of Diabetic Nephropathy. Current Vascular Pharmacology, 2020, 18, 139-147.	0.8	5
46	Carotid intimaâ€•media thickness as a targetâ€•organ damage and treatmentâ€target: Need for a major revision?. Journal of Clinical Hypertension, 2018, 20, 255-257.	1.0	4
47	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Current Vascular Pharmacology, 2018, 16, 276-288.	0.8	4
48	Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 94-103.	0.2	4
49	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. Journal of Human Hypertension, 2022, 36, 1066-1071.	1.0	4
50	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. Journal of Clinical Hypertension, 2016, 18, 1073-1073.	1.0	3
51	Abnormal blood pressure dipping in diabetic kidney disease: A blackâ€•race nightmare?. Journal of Clinical Hypertension, 2017, 19, 1336-1338.	1.0	3
52	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
53	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	0.7	3
54	Testosterone Replacement Therapy and Cardiovascular Riskâ€”A Closer Look at Additional Parameters. JAMA Internal Medicine, 2017, 177, 1393.	2.6	2

#	Article	IF	Citations
55	Subclinical target organ damage in primary aldosteronism. Journal of Hypertension, 2018, 36, 701.	0.3	2
56	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. Journal of Clinical Hypertension, 2018, 20, 634-636.	1.0	2
57	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. Journal of Clinical Hypertension, 2018, 20, 469-471.	1.0	2
58	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics, 2019, 15, 519-530.	1.0	2
59	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. Journal of Clinical Hypertension, 2019, 21, 1578-1579.	1.0	2
60	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
61	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. International Journal of Cardiology, 2020, 316, 240-241.	0.8	2
62	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. Journal of Human Hypertension, 2021, 35, 825-827.	1.0	2
63	Hypertension in Pregnancy: Unanswered Questions. Current Pharmaceutical Design, 2021, 27, 3795-3803.	0.9	2
64	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 104-113.	0.2	2
65	Impact of Primary Aldosteronism in Resistant Hypertension. Current Hypertension Reports, 2022, , 1.	1.5	2
66	Reninâ€Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. Journal of Clinical Hypertension, 2016, 18, 828-828.	1.0	1
67	Depression in hypertensive patients. Journal of Hypertension, 2016, 34, 1441.	0.3	1
68	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1295-1296.	6.3	1
69	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. Journal of Clinical Hypertension, 2018, 20, 589-591.	1.0	1
70	What is the role of statins in the elderly population?. Expert Review of Clinical Pharmacology, 2018, 11, 329-331.	1.3	1
71	Antihypertensive drug treatment: the realâ€life challenge. Journal of Clinical Hypertension, 2018, 20, 115-117.	1.0	1
72	Letter by Stavropoulos et al Regarding Article, â€œInfluence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Controlâ€. Circulation, 2018, 137, 2664-2665.	1.6	1

#	Article	IF	Citations
73	Determinants of pulse wave velocity index and potential implementations. Journal of Clinical Hypertension, 2019, 21, 1493-1495.	1.0	1
74	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. American Journal of Cardiology, 2021, 138, 116-118.	0.7	1
75	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. Current Vascular Pharmacology, 2020, 19, 313-322.	0.8	1
76	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiologia Polska, 2022, 80, 696-698.	0.3	1
77	Letter by Imprialos et al Regarding Article, â€œPolypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillationâ€. Circulation, 2016, 134, e5-6.	1.6	0
78	PATHWAY-2: spironolactone for resistant hypertension. Lancet, The, 2016, 387, 1371-1372.	6.3	0
79	Obstructive sleep apnea, hypertension, and fibrin clot properties. Journal of Hypertension, 2017, 35, 950-952.	0.3	0
80	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 83-85.	0.2	0
81	Physical Activity, Fitness, and Sexual Dysfunction. , 2019, , 373-387.		0
82	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
83	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3597-3598.	0.9	0
84	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 304, 175-176.	0.8	0
85	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 300, 119-120.	0.8	0
86	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. Angiology, 2022, 73, 000331972110055.	0.8	0
87	Current challenges in antihypertensive treatment in the elderly. Polish Archives of Internal Medicine, 2016, 126, 540-551.	0.3	0
88	Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Polish Archives of Internal Medicine, 2019, 129, 939-940.	0.3	0
89	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. Clinical and Molecular Hepatology, 2019, 25, 331-332.	4.5	0
90	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Polish Archives of Internal Medicine, 2019, 129, 648-650.	0.3	0

#	Article	IF	Citations
91	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. Journal of Diabetes and Metabolic Disorders, 0, , 1.	0.8	0
92	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients withAtype 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. Kardiologia Polska, 2022, 80, 80-82.	0.3	0